What volume in milliliters of co‑amoxiclav (amoxicillin/clavulanic acid) 457 mg per 5 mL should be administered daily for children aged 1–2, 3–4, 5–6, 7–8, and 9–10 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Co-amoxiclav 457 mg/5ml Dosing by Age

For co-amoxiclav 457 mg/5ml suspension (equivalent to 400 mg amoxicillin + 57 mg clavulanic acid per 5 mL), the standard dosing is 5 mL twice daily for children aged 1-10 years, providing approximately 45 mg/kg/day of amoxicillin in two divided doses. 1

Dosing Table by Age Range

Age Range Volume per Dose Frequency Total Daily Volume
1-2 years 5 mL Twice daily (q12h) 10 mL/day
3-4 years 5 mL Twice daily (q12h) 10 mL/day
5-6 years 5 mL Twice daily (q12h) 10 mL/day
7-8 years 5 mL Twice daily (q12h) 10 mL/day
9-10 years 5 mL Twice daily (q12h) 10 mL/day

Rationale and Key Considerations

The FDA-approved dosing for the 400 mg/57 mg per 5 mL formulation is 45 mg/kg/day divided every 12 hours for otitis media, sinusitis, lower respiratory tract infections, and more severe infections 1. This twice-daily regimen is specifically recommended because it is associated with significantly less diarrhea compared to three-times-daily dosing 1.

For less severe infections, the dose can be reduced to 25 mg/kg/day every 12 hours, which would translate to approximately 2.5-3 mL twice daily for younger children, though the standard 5 mL dose remains appropriate for most community-acquired infections 1.

Important Clinical Caveats

  • Administer at the start of meals to enhance clavulanate absorption and minimize gastrointestinal intolerance 1
  • The q12h (twice-daily) regimen is strongly preferred over q8h (three-times-daily) dosing due to better tolerability 1
  • This formulation contains aspartame and should not be used in phenylketonuric patients 1
  • Reconstituted suspension must be refrigerated and discarded after 10 days 1

Weight-Based Dosing Alternative

If precise weight-based dosing is needed for severe infections or immunocompromised patients, use 45 mg/kg/day (based on amoxicillin component) divided into two doses. For a typical child:

  • 1-2 years (10-12 kg): 225-270 mg per dose = approximately 2.5-3 mL twice daily
  • 3-4 years (14-16 kg): 315-360 mg per dose = approximately 4 mL twice daily
  • 5-6 years (18-20 kg): 405-450 mg per dose = approximately 5 mL twice daily
  • 7-8 years (22-26 kg): 495-585 mg per dose = approximately 5-7 mL twice daily
  • 9-10 years (28-32 kg): 630-720 mg per dose = approximately 7-9 mL twice daily

However, the standard 5 mL twice-daily dose is appropriate and FDA-approved for all children in the 1-10 year age range for most indications 1.

Guideline Context

British guidelines for pandemic influenza previously recommended age-based dosing of co-amoxiclav 125/31 suspension (5 mL three times daily for ages 1-6 years) 2, and the British Thoracic Society guidelines for community-acquired pneumonia recommended similar age-stratified dosing 3. However, the current FDA-approved formulation of 400/57 mg per 5 mL with twice-daily dosing supersedes these older recommendations and provides superior coverage with better tolerability 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.